High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review

Sophie L. Gerritse, Jorien B.E. Janssen, Mariette Labots, Ralph de Vries, Michelle Rudek, Michael Carducci, Nielka P. van Erp, Henk M.W. Verheul

Research output: Contribution to journalReview articlepeer-review

Abstract

Background: Innovative strategies to fully exploit the antitumor activity of multitargeted tyrosine kinase inhibitors (TKIs) are urgently needed. Higher concentrations of TKIs at their target site, i.e. intratumorally, may lead to broader kinase inhibition, which might be essential for the optimal suppression of tumor growth and induction of apoptosis. To reach these higher intratumoral concentrations, without encountering dose limiting toxicity, alternative TKI dosing strategies employing higher daily and high intermittent doses have been studied. In this systematic review, we evaluated the current clinical evidence to support (intermittent) high TKI dosing regimens. Methods: A systematic review was conducted in the following databases: PubMed®, EMBASE® and Cochrane Library

Original languageEnglish (US)
Article number102171
JournalCancer Treatment Reviews
Volume97
DOIs
StatePublished - Jun 2021

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review'. Together they form a unique fingerprint.

Cite this